Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Malignant maxillofacial extra-nodal lymphoma].

H Szpirglas1, P Goudot, A Thomas

  • 1Service de stomatologie et chirurgie maxillo-faciale, C.H.U. Pitié-Salpêtrière, Paris.

Revue De Stomatologie Et De Chirurgie Maxillo-Faciale
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.

Clinical neuropharmacology·2001
Same author

Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice.

The Journal of biological chemistry·2001
Same author

Somatostatin, its receptors and analogs, in lung cancer.

Chemotherapy·2001
Same author

[A study on abnormal chondrocyte differentiation and abnormal expression of collagen types in articular cartilage from patients with Kaschin-Beck disease].

Zhonghua bing li xue za zhi = Chinese journal of pathology·2001
Same author

Improved flow cytometric detection of HLA alloantibodies using pronase: potential implications in renal transplantation.

Transplantation·2001
Same author

Rapid detection of resistance to rifampicin in Mycobacterium leprae.

Leprosy review·2001
Same journal

[Proceedings of the 48th Congress SFSCMF Surgery and pre-implantation and implantology,27–29 September 2012, Versailles, France].

Revue de stomatologie et de chirurgie maxillo-faciale·2013
Same journal

[Contribution and limitations of MIS(®) screwed expanders in the jaws: illustration from clinical cases and comparison of the osseous volume from three-dimensional radiographic pictures].

Revue de stomatologie et de chirurgie maxillo-faciale·2012
Same journal

[Complications of head and neck skin expansion].

Revue de stomatologie et de chirurgie maxillo-faciale·2012
Same journal

[Complex fronto-orbital reconstruction with a PEEK prosthesis and skin expansion: about a case].

Revue de stomatologie et de chirurgie maxillo-faciale·2012
Same journal

[PEEK customized implant for skull esthetic reconstruction].

Revue de stomatologie et de chirurgie maxillo-faciale·2012
Same journal

[Subcutaneous malar nodule].

Revue de stomatologie et de chirurgie maxillo-faciale·2012
See all related articles

This study on extra-nodal maxillo-facial Non-Hodgkin Lymphoma (NHL) found it primarily affects men aged 40-70. Chemotherapy offers a 50% survival rate at 3 years for these rare, aggressive tumors.

Area of Science:

  • Oncology
  • Maxillofacial Surgery
  • Hematology

Context:

  • Extra-nodal Non-Hodgkin Lymphoma (NHL) of the maxillo-facial region is rare, accounting for 1-4% of stomatological tumors.
  • Observed in 64 patients between 1969 and 1989.

Purpose:

  • To describe the clinical characteristics, treatment, and outcomes of patients with extra-nodal maxillo-facial NHL.
  • To analyze the incidence and presentation of these rare malignancies.

Summary:

  • The tumors predominantly affected men (60%) aged 40-70.
  • Common presentations included bony involvement (maxilla, mandible) and less frequently salivary glands or mucosa, appearing as swelling with bone lysis.
  • Highly malignant varieties constituted 85% of cases.

Related Experiment Videos

Impact:

  • Medical treatment, primarily chemotherapy (Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone - CHOP, or high-dose methotrexate), resulted in an actuarial survival rate of 50% at 3 years.
  • Highlights the aggressive nature and challenges in treating maxillo-facial NHL.